A new daily weight loss pill called orforglipron, manufactured by Eli Lilly, has demonstrated superior results to Wegovy in a clinical trial of over 1,500 adults with type 2 diabetes across five countries. After 12 months, participants taking orforglipron experienced 6-8% weight loss compared to 4-5% with oral semaglutide, along with bigger drops in average blood sugar levels. However, orforglipron caused more severe gastrointestinal side effects including vomiting and diarrhoea, leading up to 10% of trial participants to discontinue use, and the medication is still awaiting regulatory approval in Australia.

7News Just In is a daily podcast that brings you Australia's latest news. 

<p>7News Just In is a daily podcast that brings you Australia's latest news. </p>

7News Just In

New weight loss pill outperforms rivals but causes side effects

https://api.omny.fm/orgs/fa326977-3de5-4283-9b8b-af3500c58607/clips/5b643c28-9e04-4310-86fc-b3fe0063d340/transcript